No profile data available.
Harrow, Inc. (HROW) is a healthcare company in the additional drug wholesale industry, based in Nashville, United States, with about 373 full-time employees.
It reported revenue of $272.30 million for fiscal year 2025, up 36.4% from fiscal year 2024, and net income of -$5.14 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $70.66 million, up 10.9% from a year before. Its largest business segment, Branded, brought in 72% of segment revenue in fiscal year 2025. Its market capitalization was $1.10 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications.
Harrow reported $272.30 million in revenue for fiscal year 2025, up 36.4% from $199.61 million in fiscal year 2024. In Q2 2026 revenue was $70.66 million.
Branded, with $195.76 million or 72% of segment revenue in fiscal year 2025. Next: Compounding (28%).
$1.10 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional drug wholesale) include Cencora, Inc. (COR), Cardinal Health, Inc. (CAH), BrightSpring Health Services, Inc. (BTSG), Earth Science Tech, Inc. (ETST).